> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# ARK Reports About 7% Of Absci — Its Stake Carries No Control Aim
- URL: https://www.bullished.co/ark-reports-about-7-of-absci-its-stake-carries-no-control-aim-80ec55d2/
- Published: 2026-11-13T18:21:10.000Z
- Updated: 2026-11-13T18:21:10.000Z
- Description: ARK Genomic Revolution ETF was the only client with an interest above 5% in the reported shares.
- Author: Matteo Parrino
- Tags: SEC Filings, ABSI, Industry: Healthcare, Topic: Ownership & Activism

ARK Investment Management reported [about 7%](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126821/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) of [Absci](https://www.bullished.co/tag/absi/), which uses AI and laboratory testing to develop antibody drugs, in a passive ownership disclosure filed Friday. The position covered September 30, and ARK certified that it held the shares for ordinary business purposes without seeking to change or influence company control.

## One Position, Shared Reporting

ARK reported 11,928,917 common shares, equal to 6.95% of the class on the disclosure's beneficial-ownership basis. ARK Genomic Revolution ETF, a client of the investment manager, was the [only client above](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126821/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) the 5% interest threshold for those securities.

Catherine D. Wood, ARK's [chief executive officer](https://www.sec.gov/Archives/edgar/data/1697748/000110465926126821/tm2629184d2%5Fex1.htm?ref=bullished.co) and chief investment officer, joined the disclosure as a reporting person. Her reported share count matched ARK's: both entries described the same position.

ARK reported sole authority to vote the shares and decide their disposal. Wood reported shared authority for both. The share counts therefore describe overlapping reporting authority, not separate holdings to add together.

The control certification covers both the purpose of holding the securities and participation in transactions aimed at changing or influencing control, with an exception for activities solely connected to a nomination under the specified SEC rule.

## AI Drug Discovery And Owned Medicines

Absci develops medicines of its own and works on drug discovery with pharmaceutical and biotechnology partners, including Merck, AstraZeneca and Almirall. Its collaborations can produce upfront payments, research fees, milestone payments and royalties.

The company's lead drug candidate, ABS-201, is being developed for pattern hair loss and endometriosis. Clinical testing is underway for hair loss.

As of December 31, 2025, Absci was advancing five internally developed programs that it wholly owned, along with additional programs in early discovery. Its drug-creation platform uses combined laboratory space exceeding 77,000 square feet.

ARK's exchange-traded funds hold concentrated positions in small and midsize companies. Those holdings frequently cross reporting thresholds; ARK generated about 170 ownership schedules over two years.

Absci's market value was $1.6 billion in Friday trading as of 1:16 p.m. ET.

The reported ownership gives ARK voting and disposal authority over a substantial Absci position, while its certification places that holding outside an effort to change company control.

Learn

- [13D Filing Requirements And Deadline, Shown With Real Filings →](https://www.bullished.co/learn/13d-filing-requirements/)  
A Schedule 13D is required when you own more than 5% of a public company's voting shares. See the deadline, contents and real filings from this week.
- [13D Vs 13G: What Each 5% Stake Filing Means And How To Read One →](https://www.bullished.co/learn/13d-vs-13g/)  
13D vs 13G: both report stakes above 5%, but 13G is the short passive form and 13D explains intent. See real BlackRock and Pictet filings read in plain English.

### Sources

- [SCHEDULE 13G/A — ARK Investment Management LLC re: Absci Corp (ABSI)](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126821/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13G/A Exhibit 1 — EXHIBIT 1](https://www.sec.gov/Archives/edgar/data/1697748/000110465926126821/tm2629184d2%5Fex1.htm?ref=bullished.co) — SEC EDGAR

### More on Absci

- [Absci Stock Plunges 7% After Its Quarterly Loss Widens](https://www.bullished.co/absci-stock-plunges-7-after-its-quarterly-loss-widens-2123d953/)
- [Absci Keeps Its Thicker-Hair Benchmark As It Makes The Case For Counting Fine Hairs](https://www.bullished.co/absci-keeps-its-thicker-hair-benchmark-as-it-makes-the-case-for-counting-fine-hairs-67cf63a7/)
- [Absci Expects Cash To Fund Operations Into 2028 As It Builds A Commercial Team](https://www.bullished.co/absci-expects-cash-to-fund-operations-into-2028-as-it-builds-a-commercial-team-00651985/)

[All Absci (ABSI) coverage →](https://www.bullished.co/tag/absi/)